{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ramondetta LM"],"funding":["Blanton-Davis Ovarian Cancer Research Program","NCI NIH HHS","Frank McGraw Memorial Chair in Cancer Research","National Institutes of Health"],"pagination":["524-530"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6867685"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["154(3)"],"pubmed_abstract":["<h4>Objective</h4>To determine the feasibility of pharmacologic beta-adrenergic blockade in women with newly diagnosed stage II-IV epithelial ovarian cancer (EOC) throughout primary treatment.<h4>Methods</h4>Patients initiated propranolol prior to beginning chemotherapy or surgery. Feasibility was assessed as proportion able to complete 6 chemotherapy cycles while on adrenergic suppression. Descriptive statistics summarized surveys, and paired changes were analyzed using signed rank tests. Random-intercept Tobit models examined immune response.<h4>Results</h4>Median age was 59.9; 88.5% were stage IIIC/IV; and 38.5% underwent primary debulking. Thirty-two patients were enrolled; 3 excluded because they never took propranolol; an additional 3 didn't meet inclusion criteria, leaving 26 evalua"],"journal":["Gynecologic oncology"],"pubmed_title":["Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression."],"pmcid":["PMC6867685"],"funding_grant_id":["P30 CA016672","CPRIT RP210214","P50 CA217685"],"pubmed_authors":["Sood AK","Fleming N","Arevalo JMG","Hu W","Coleman RL","Thaker PH","Sahai SK","Ramondetta LM","Sun Y","Urbauer DL","Cole SW","Westin SN","Dizon T","Ramirez PT","Chisholm GB","Nick AM"],"additional_accession":[]},"is_claimable":false,"name":"Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.","description":"<h4>Objective</h4>To determine the feasibility of pharmacologic beta-adrenergic blockade in women with newly diagnosed stage II-IV epithelial ovarian cancer (EOC) throughout primary treatment.<h4>Methods</h4>Patients initiated propranolol prior to beginning chemotherapy or surgery. Feasibility was assessed as proportion able to complete 6 chemotherapy cycles while on adrenergic suppression. Descriptive statistics summarized surveys, and paired changes were analyzed using signed rank tests. Random-intercept Tobit models examined immune response.<h4>Results</h4>Median age was 59.9; 88.5% were stage IIIC/IV; and 38.5% underwent primary debulking. Thirty-two patients were enrolled; 3 excluded because they never took propranolol; an additional 3 didn't meet inclusion criteria, leaving 26 evalua","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2025-06-01T12:00:33.757Z","creation":"2020-09-05T07:03:38Z"},"accession":"S-EPMC6867685","cross_references":{"pubmed":["31353053"],"doi":["10.1016/j.ygyno.2019.07.004"]}}